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Abstract 17 
ES-62, a glycoprotein secreted by the parasitic filarial nematode Acanthocheilonema viteae, 18 
subverts host immune responses towards anti-inflammatory phenotypes by virtue of 19 
covalently attached phosphorylcholine (PC). The PC dictates that ES-62 exhibits protection 20 
in murine models of inflammatory disease and hence a library of drug-like PC-based small 21 
molecule analogues (SMAs) was synthesised. Four sulfone-containing SMAs termed 11a, 22 
11e, 11i and 12b were found to reduce mouse bone marrow-derived dendritic cell (DC) 23 
pathogen-associated molecular pattern (PAMP)-induced pro-inflammatory cytokine 24 
production, inhibit NF-ț% p65 activation, and suppress LPS-induced up-regulation of CD40 25 
and CD86. Active SMAs also resulted in a DC phenotype that exhibited reduced capacity to 26 
prime antigen (Ag)-specific IFN-Ȗproduction during co-culture with naïve transgenic TCR 27 
DO.11.10 T cells in vitro and reduced their ability, following adoptive transfer, to prime the 28 
expansion of Ag-specific T lymphocytes, specifically TH17 cells, in vivo. Consistent with 29 
this, mice receiving DCs treated with SMAs exhibited significantly reduced severity of 30 
collagen-induced arthritis and this was accompanied by a significant reduction in IL-17+ cells 31 
in the draining lymph nodes. Collectively, these studies indicate that drug-like compounds 32 
that target DCs can be designed from parasitic worm products and demonstrate the potential 33 
for ES-62 SMA-based DC therapy in inflammatory disease.  34 
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Introduction 40 
Dendritic cells (DCs) are professional antigen (Ag)-presenting cells that provide a critical 41 
link between the innate and adaptive immune systems. They recognise pathogen-associated 42 
molecular patterns (PAMPs), as well as host danger signals, through conserved pattern 43 
recognition receptors (PRRs) such as the Toll-like receptors (TLRs)1. Upon recognition of 44 
Ag, DCs leave the peripheral tissue and migrate to the lymph nodes (LNs) where they initiate 45 
an adaptive immune response via their interactions with naïve T cells. The type of T cell 46 
response generated depends on the secondary signals provided by the DC. Thus, TLR 47 
recognition of bacterial or viral ligands induces DC maturation which results in the priming 48 
of T helper cell 1 (TH1)/TH17 responses through secretion of pro-inflammatory cytokines 49 
such as IL-12, IL-6 and TNF-Į, and up-regulation of co-stimulatory molecules including 50 
MHC II, CD40, CD80 and CD862. Recognition of parasitic helminth molecules by DCs does 51 
not induce such classical activation, but rather promotes a phenotype that more closely 52 
resembles that of immature DCs, characterised by low expression of co-stimulatory 53 
molecules and muted secretion of pro-inflammatory cytokines. Moreover, these DCs are 54 
refractory to subsequent classical activation through stimulation with TLR ligands such as 55 
LPS3. Nevertheless, such DCs still appear capable of generating strong TH2 responses, which 56 
may be accompanied by induction of a regulatory T cell (Treg) phenotype4,5.  57 
ES-62, a glycoprotein secreted by the rodent filarial nematode Acanthocheilonema viteae, 58 
was the first parasitic helminth molecule found to modulate the ability of DCs to prime 59 
polarised TH responses when it was shown that DCs matured with ES-62 promote Ag-60 
specific IL-4 production by T cells whilst inhibiting their capacity to produce IFN-Ȗin vitro6. 61 
This reflects that DCs exposed to ES-62 in vitro or in vivo, exhibit decreased capacity to 62 
generate pro-inflammatory responses to TLR2, 4 and 9 ligands (BLP, LPS and CpG), as 63 
evidenced by their reduced production of pro-inflammatory cytokines such as IL-12 and 64 
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TNF-Į7. Consistent with this ability to suppress such pro-inflammatory responses, ES-62 has 65 
also been demonstrated to be protective in several murine models of TH1/TH17-mediated 66 
inflammatory disease, for example, collagen-induced arthritis (CIA), although in this model 67 
ES-62 does not appear to induce compensatory TH2 responses
8. The protective effects raise 68 
the possibility of utilising ES-62 therapeutically, but as a large, potentially immunogenic 69 
molecule, it is unsuitable for development as a treatment for human disease. However, as 70 
post-translational attachment of phosphorylcholine (PC) to N-glycan moieties has been 71 
shown to be responsible for the majority of ES-¶V anti-inflammatory effects (reviewed in8), 72 
a library of small molecule analogues (SMAs) of ES-62 based around PC has been designed 73 
and synthesised with the aim of finding the best way of presenting this immunomodulatory 74 
component in drug-format.  75 
Two of these SMAs, sulfone compounds termed 11a and 12b, have previously been 76 
demonstrated to modulate macrophage and mast cell responses and, as with ES-62, to protect 77 
against development of CIA in mice9±11. Given the pivotal role of DCs in the protection 78 
afforded by ES-62 in suppressing IL-17 responses in CIA12, we wished to determine whether 79 
DCs were a therapeutic target for the SMAs: we now show that SMAs 11a and 12b, along 80 
with two other sulfones - 11e and 11i, indeed modulate DC responses in vitro such that the 81 
cells are refractory to subsequent activation by TLR-PAMPs and are similarly characterised 82 
by their reduced expression of co-stimulatory molecules CD40 and CD86, inhibited 83 
production of IL-12, IL-6 and TNF-Į, and abrogated priming of Ag-specific TH1 responses. 84 
The sulfones 11e and 11i, unlike 11a and 12b, have not yet been studied much further than 85 
the primary response of the cytokine release profile; 11e and 11i are close structural 86 
analogues of 11a having 3- and 4- fluoro substituents in the benzene ring in place of the 4-87 
bromo substituent in 11a. Expanding the structural diversity available in active SMAs is 88 
valuable not only from the point of view of scientific understanding but also from the point of 89 
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view of potential therapeutic applications of SMAs. In addition, we demonstrate that transfer 90 
of SMA-treated DCs into mice suppresses Ag-specific clonal expansion and TH17 91 
polarisation. Finally, consistent with recent reports that helminth-matured DCs can influence 92 
autoimmune disease progression in mouse models13±15, simply adoptively transferring DCs 93 
treated with 11a plus 12b was found to suppress the severity of development of CIA. As such 94 
DCs mimic the previously reported effects in CIA observed when these SMAs were 95 
administered directly, these findings support the therapeutic potential of SMA-DC therapy in 96 
inflammatory diseases such as RA.  97 
 6 
Results 98 
Small molecule analogues (SMAs) of ES-62 modulate dendritic cell responses 99 
The library (79 SMAs;9) was initially screened in vitro to determine the effect of SMAs on 100 
subsequent PAMP-mediated pro-inflammatory cytokine production by bmDCs 101 
(Supplementary Table 1) in order to identify any SMAs that could mimic the previously 102 
reported modulatory effects of ES-62 (reviewed by 16). Sulfone-type SMAs 11a, 11e, 11i and 103 
12b (structures shown in Figure 1A-D) each reduced the LPS-stimulated production of IL-6, 104 
TNF-ĮDOWKRXJKWKLVGLGQRWUHDFKstatistical significance in all experiments with 11a) and 105 
IL-12(p70) (Figure 1E-G, left hand panels). It was next investigated whether these SMAs 106 
were also capable of inhibiting the cytokine responses induced by ligands of TLR2 and TLR9 107 
as both of these PRRs, along with TLR3 and TLR4, are thought to play an important role in 108 
the pathogenesis of RA17,18. SMAs 11e and 12b significantly inhibited BLP- and CpG-109 
induced IL-6, TNF-Įand IL-12(p70) secretion while 11i significantly inhibited all of these 110 
responses except BLP-induced TNF-Į (Figure 1E-G, middle and right hand panels). SMA 111 
11a demonstrated the most selectivity as it did not inhibit BLP-induced TNF-ĮDQG&S*-112 
induced IL-6 but all other responses were reduced (Figure 1E-G, middle and right hand 113 
panels). However, none of the SMAs inhibited the production of IL-12p40; indeed, 11a 114 
significantly increased the BLP- and LPS-induced production of this cytokine by bmDCs 115 
(data not shown), suggesting that as with ES-62, IL-12p35 may be the major target19 in the 116 
suppression of IL-12p70. Overall, the observed selectivity in response was not found when 117 
testing the SMAs on macrophages9 suggesting that the compounds may exhibit differential 118 
effects in distinct cell types. 119 
As the SMAs inhibited IL-12p70 but not IL-12p40 following PAMP stimulation we next 120 
investigated whether IL-12p35 and IL-12p40, were differentially regulated at the mRNA 121 
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level by the SMAs. Consistent with the protein secretion data, whilst SMAs 11a and 12b had 122 
no significant inhibitory effect on the LPS-induced levels of p40, and in fact increased the 123 
basal levels (data not shown), they significantly reduced LPS-induced p35 expression (Figure 124 
2A, B). However, SMAs 11e and 11i significantly inhibited the LPS-stimulated expression of 125 
both IL-12 subunits (Figure 2A, B) as well as the basal levels of IL-12p35 but not IL-12p40 126 
(data not shown). In addition, all four SMAs significantly inhibited the level of LPS-induced 127 
IL-6 and TNF-ĮJHQHH[SUHVVLRQLQGLFDWLQJWKH\likely target these cytokines at the 128 
transcription/message stability level (Figure 2C, D).  129 
ES-62 differentially targets ERK and p38 MAPK signalling to mediate suppression of IL-130 
12p40 and p35 subunits, with inhibition of p38 resulting in reduced production of p35 (and 131 
IL-6) whilst augmentation of ERK-mediated negative feedback mediates suppression of p40 132 
production in LPS + IFNJstimulated macrophages19. Incubation of bmDCs with SMAs 133 
alone did not alter the activation of either p38 or ERK MAPK (data not shown) whereas 134 
stimulation of the cells with LPS for 10 min resulted in significant activation of both ERK 135 
and p38 MAPK. Consistent with its ability to inhibit IL-12p35 and IL-6 production, pre-136 
treatment with SMA 12b significantly suppressed LPS-stimulated p38 activation but 137 
interestingly none of the other SMAs had any significant effects on this MAPK (Figure 2E 138 
and data not shown). Likewise, SMA 12b, but not the other SMAs, caused a reduction in the 139 
LPS-mediated ERK activation (Figure 2F and data not shown). 140 
The suppression of PAMP-induced cytokine release by ES-62 or the SMAs 11a and 12b in 141 
macrophages and mast cells is also associated with inhibition of RelA p65 NF-ț%9,11, 142 
although such an effect of the SMAs in DCs has not previously been investigated. Analysis of 143 
the levels of p65 activation in bmDCs after SMA pre-treatment and LPS stimulation in the 144 
present study revealed that 11a, 12b and 11e inhibited NF-ț%DFWLYDWLRQ as shown when 145 
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compared to results obtained in response to treatment with LPS alone (Figure 2G), although 146 
SMA 11i had an inconsistent effect on the activation of p65 (data not shown). Treatment with 147 
SMAs alone had no effect on the basal activation of p65 NF-ț%data not shown).  148 
ES-62 SMAs modulate the ability of DCs to drive TH1/TH17 responses  149 
The cytokines produced by DCs and the co-stimulatory molecules that they express when 150 
they present Ag to naïve T cells play a key role in the polarisation and development of the 151 
subsequent immune response. As we have shown the SMAs to inhibit the pro-inflammatory 152 
cytokine production of DCs, it was next investigated whether they also affect their co-153 
stimulatory molecule expression following LPS maturation: indeed, pre-treatment with all 154 
four SMAs significantly reduced the LPS-induced up-regulation in the proportion of cells 155 
expressing CD40 or CD86 (Figure 3A, B). In addition, we checked the levels of expression 156 
(MFI) and whereas this was also reduced with respect to CD40, this was not the case for 157 
CD86 (Figure 3A, B). 158 
It was next therefore investigated whether SMA-mediated modulation of DC maturation 159 
could alter the ability of the cells to prime T cell responses in vitro. Treatment of DCs with 160 
ES-62 was previously demonstrated to promote the Ag-specific priming of IL-4 release by 161 
naïve T cells and inhibit their production of IFN-ȖSRODULVLQJthe cells away from a TH1 162 
response6. Likewise, ES-62 has been shown to suppress the DC-priming of TH17 cells, 163 
thereby blocking responses associated with pathogenesis in CIA12. Investigation of the SMAs 164 
revealed that they similarly suppressed (in this case, completely) the priming of IFN-Ȗ165 
(Figure 3C) suggesting that SMA-exposure can also modulate the ability of bmDCs to prime 166 
TH1 cytokine responses in naïve CD4
+CD62L+ T cells. However, IL-17 and IL-4 production 167 
could not be detected in these experiments (data not shown). 168 
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The physiological relevance of these findings was investigated by determining whether DCs 169 
exposed in vitro to LPS, SMAs, or SMAs + LPS, primed differential T cell responses in vivo. 170 
Specifically, medium alone (RPMI)-, LPS-, SMA- or SMA+LPS-exposed DCs were 171 
transferred into recipient BALB/c mice 24 h after they had received DO.11.10 T cells 172 
expressing the transgenic KJ1.26+ TCR specific for OVA323-339. We have previously used this 173 
model to demonstrate ES-62-mediated suppression of clonal expansion and re-polarisation of 174 
the effector function of heterologous antigen-specific T cells away from both TH1 and TH2 175 
responses in vivo20,21. Moreover, pretreatment with ES-62 was found to suppress the ability of 176 
LPS-matured DCs to initiate Ag-specific responses upon adoptive transfer22. As shown 177 
previously22, transfer of OVA peptide-loaded DCs matured with LPS induced high levels of 178 
Ag-specific T cell expansion compared to control RPMI DCs at day 5 post inoculation while 179 
DCs loaded with OVA peptide alone induced a modest increase in the number of these cells 180 
(Figure 3D). Pre-exposure of DCs to either SMA 11a or 11i before LPS stimulation 181 
significantly reduced both the percentage and number of CD4+KJ1.26+ T cells in the dLNs 182 
when compared to those obtained with control OVA + LPS-DCs on this day (Figure 3E, F). 183 
Additionally, mice receiving DCs treated with SMA 11i had a significantly reduced 184 
percentage and number of CD4+KJ1.26+ T cells compared to mice inoculated with control 185 
OVA-DCs on days 3 and 5, and a reduced number of these cells on day 5 (Figure 3E, F). DCs 186 
treated with SMA 11a also had a reduced percentage of CD4+KJ1.26+ cells on day 3 but not 187 
day 5, relative to control OVA-DCs (Figure 3E).  188 
We also examined whether such SMA-exposed DCs and SMA+LPS-exposed DCs altered the 189 
polarisation of CD4+ T cells away from the TH1/TH17 responses observed in this in vivo 190 
setting.  Mice adoptively transferred with 11a+LPS-DCs or 11i+LPS-DCs demonstrated 191 
significantly reduced levels ± both numbers and percentages - of IL-17+ and IFN-Ȗ+ T cells 192 
compared to those with LPS-DCs (Figure 3G-J). SMA 11i-DC inoculated mice also had 193 
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significantly lower numbers of IFN-Ȗ+ and IL-17+ CD4+ T cells compared to OVA-DC 194 
inoculated mice, although with IFNJ this did not reach statistical significance (Figure 3G-J). 195 
Interestingly, treatment with either SMA (although not always reaching statistical 196 
significance) also tended to reduce the (low) percentages and levels of IL-4 cells (Figure 3K, 197 
L) induced by LPS-DCs, indicating that while the SMAs may be able to attenuate TH1/TH17 198 
responses in vivo, like ES-6212,23 they do not tend to induce the opposing TH2 phenotype.  199 
SMA-treated DCs protect against the development of collagen-induced arthritis 200 
The ES-62-mediated protection against CIA is associated with suppression of TH1, TH17 and 201 
IL-17-producing JG T cell responses and this reflects modulation of DC function with bmDCs 202 
from ES-62-treated CIA mice exhibiting a reduced capacity to produce IL-6, TNF-Į and IL-203 
2312. Likewise ES-62-treated DCs display a reduced ability to generate OVA-specific TH1 204 
and TH17 cells and such modulation of DC function was found to be responsible for the ES-205 
62-mediated suppression of IL-17 responses by Ȗį7FHOOV12. Collectively these data suggest 206 
that DCs are a central target in ES-62-mediated protection during development of CIA. Thus, 207 
as both 11a and 12b have been found to be protective in prophylactic and therapeutic models 208 
of CIA9,11 and 11a-modulated DCs were found to inhibit both TH1 and TH17 responses that 209 
are crucial for the development of CIA in the adoptive transfer model, it was decided to 210 
compare the effects of DCs treated with SMAs 11a and 12b in combination ³60$'&V´RQ211 
CIA with those of control '&V³530,'&V´DQGdisease-control CIA mice exposed only to 212 
PBS.  213 
Administration of in vitro SMA-matured bmDCs but not RPMI DCs, was indeed found to 214 
ameliorate CIA as evidenced by reduced arthritic score and suppressed cellular infiltration 215 
and damage to the joints (Figure 4A, B). However, SMA-treated DCs did not modulate the 216 
CII-specific antibody responses as the levels of CII-specific IgG1 and IgG2a antibodies were 217 
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unchanged amongst PBS-, RPMI DC- and SMA DC-inoculated mice (Figures 4C, D). 218 
Previous studies, which have demonstrated protective effects of helminth-matured DCs, have 219 
reported that such protection is mediated through the generation of Treg cells and/or the 220 
production of IL-1013±15. It was therefore investigated whether SMA-matured DCs also 221 
mediated protection through these mechanisms. Consistent with studies with ES-6220,24, there 222 
was no difference in the percentage of FOXP3+CD4+ Tregs cells in the dLNs of treated mice 223 
relative to the other groups, nor was there any difference in the expression of IL-10 by these 224 
cells (Figure 4E and data not shown). Nor were there any differences amongst the groups in 225 
the percentages of CD4+IL-10+ Tr1 cells (Figure 4F). While ES-62 does not seem to promote 226 
the generation of Tregs it has recently been found that the nematode product restores IL-10-227 
producing B cell levels in CIA-mice back to those present in naïve mice25. However, there 228 
was also no difference in the levels of IL-10+CD4- cells found amongst the treatment groups 229 
(Figure 4G).  230 
As stated above, ES-62 mediates protection in CIA through the down-regulation of pro-231 
inflammatory cytokines, in particular IL-17, and by targeting a complex network of cells, 232 
specifically through modulation of DCs9,12 and thus the levels of IL-17-producing cells in the 233 
dLNs were analysed by flow cytometry. SMA DC-treated mice exhibited a significantly 234 
reduced proportion of IL-17+ CD4+ T cells in the dLNs compared to RPMI DC- and PBS-235 
exposed mice (Figure 5A). In addition, mice treated with SMA-DCs had a significantly 236 
reduced proportion of IL-17+ CD4- cells that potentially represent Ȗį7FHOOVin the 237 
lymphocyte gate, compared to mice treated with RPMI-DCs or PBS (Figure 5B). 238 
Furthermore, SMA-DC treated mice had reduced levels of IL-17 staining in their joints 239 
compared to RPMI-DC and PBS-treated mice (Figure 5C). There were no differences 240 
amongst the groups in the proportion of CD4+ T cells in the DLNs expressing IFNJ but a 241 
significant increase in the percentage of non-CD4+ cells expressing IFNJ was observed, and 242 
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this was significantly decreased in mice inoculated with RPMI-DCs or SMA-DCs (Data not 243 
shown).  244 
SMA 12b has been demonstrated to mediate its protective effect in CIA via suppression of 245 
IL-ȕUDWKHUWKDQIL-17, responses11. Thus, it was investigated if protection afforded by 246 
SMA-DC treatment was also mediated through modulation of IL-ȕ. Although no IL-ȕcould 247 
be detected in serum obtained from mice with CIA (results not shown), staining of IL-ȕLQ248 
the joint revealed that treatment with SMA-DCs greatly reduced expression of this cytokine 249 
compared to levels pertaining in mice treated with RPMI-DC or PBS (Figure 5C). Supporting 250 
this finding, and consistent with our previous results in macrophages11, incubation with SMA 251 
12b (or 11a/12b in combination) for 4 hours was found to inhibit the steady-state mRNA 252 
expression of IL-ȕLQ'&V, an effect not noted with the other SMAs (Figure 5D). Regarding 253 
mechanism, we have also previously shown in macrophages that SMA 12b acts to suppress 254 
IL-ȕUHVSRQVHVE\UHGXFLQJ1/53LQIODPPDVRPHH[SUHVVLRQLQDQ15)-dependent 255 
manner11 and consistent with this, 12b and 11a/12b combination, but not 11a, 11e or 11i, 256 
similarly suppress NLRP3 (Figure 5E) whilst inducing HMOX (a cyto-protective gene target 257 
of NRF2) gene expression in DCs over 4 hours (Figure 5F). We also measured the release of 258 
IL-1E protein resulting from stimulation over 24 hours of DCs with BLP, a ligand of TLR2 259 
signalling which has been proposed to play a key pathogenic role in the arthritic joint18 and 260 
found it to be reduced (Figure 5G). Interestingly however, this effect was also noted with the 261 
other 3 SMAs, with 11e and 11i being particularly effective (Figure 5G), perhaps suggesting 262 
that these SMAs may also target NLRP3 activation in DCs. In addition, it has recently been 263 
shown that PC can inhibit release of IL-1E from human and rat monocytes in response to LPS 264 
and ATP26, and similarly we found that all four SMAs could significantly reduce release of 265 
the cytokine from mouse bmDCs in response to this combination of stimuli (Figure 5H). Here 266 
11a was noted as being particularly potent, being as effective as 11a and 12b in combination. 267 
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Recently it has emerged that the inflammasome is important in the development of IL-17 268 
responses27, and therefore the SMAs may be mediating protection against CIA by targeting 269 
differing aspects of this interrelated response. Nevertheless, although not always reaching 270 
statistical significance, there is a trend for the SMAs other than 12b to exhibit similar effects 271 
on gene expression to the latter SMA when this is measured over 18 hours (results not 272 
shown).  273 
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Discussion 274 
Modulation of DC responses is a key mechanism by which ES-62 mediates many of its anti-275 
inflammatory effects6,12,20 and here we demonstrate that four synthetic ES-62 SMAs - 11a, 276 
11e, 11i and 12b, are similarly capable of targeting these cells. Studies in vitro revealed that 277 
like ES-62, the SMAs render bmDCs refractory to full activation by TLR PAMPs, as 278 
evidenced by decreased expression of co-stimulatory molecules and reduced release of pro-279 
inflammatory cytokines. One difference we noted however, is that in contrast to ES-62, the 280 
SMAs have no obvious inhibitory effect on IL-12p40 protein production (in spite of 11e and 281 
11i reducing mRNA production), but significantly suppress generation of IL-12(p70). We 282 
wished to gain some understanding of the molecular mechanisms underlying these effects and 283 
have previously found ES-62 to differentially modulate activation of MAPKs to mediate its 284 
anti-inflammatory effects on cytokine production. For example, whilst the nematode product 285 
induces ERK MAPK activation to negatively regulate IL-12p40 production, it suppresses the 286 
p38 activation required for generation of IL-12p35, IL-6 and TNF-D in macrophages. SMA 287 
12b likewise significantly inhibited the LPS-induced activation of p38 in bmDCs consistent 288 
with its ability to suppress IL-12p35, IL-6 and TNF-D mRNA in these cells. However, it 289 
inhibited rather than activated LPS-induced ERK production and this may explain its failure 290 
to reduce IL-12p40 production. Moreover, ERK activation has been linked to TH2 responses 291 
and this signal transducer has been shown to be preferentially activated (phosphorylated) by 292 
helminth products, such as LNFPIII, a glycan found in soluble schistosome egg antigen 293 
(SEA), to help drive the TH2 response conducive to helminth survival
28. Thus, as 12b 294 
suppressed LPS-induced ERK activation it is possible that it could target TH2 in addition to 295 
TH1 responses, although neither 11a nor 11i significantly inhibited such ERK activation 296 
despite 11a/11i-treated DCs tending to suppress Ag-specific TH2 responses in the in vivo 297 
adaptive transfer model. SMAs 11a and 11e also reduced ERK and p38 MAPK activation but 298 
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this did not reach significance in all experiments. Instead, these SMAs, along with 12b, were 299 
found to significantly reduce the level of activation of NF-ț% p65 in response to LPS. 300 
Inhibition of NF-ț%KDVEHHQIRXQGWRUHWDLQ'&VLQDQLPPDWXUHVWDWH29,30, a mechanism 301 
used by other parasites including F. hepatica and Brugia malayi to modulate APC-priming of 302 
immune responses31±33. SMA 11i had no consistent effect on NF-ț% p65 activation and, 303 
similar to 11a and 11e, reduced ERK and p38 MAPK but not significantly, suggesting that it 304 
may target other molecules to mediate its effects. Further understanding of how the SMAs 305 
mediate their inhibitory effects will require fully elucidating the nature of the signal 306 
transducers that they interact with, and also establishing whether like ES-62 they require a 307 
specific receptor for cell entry34.  308 
In vitro exposure of DCs to SMAs also impacted on their activity in vivo. For example, pre-309 
exposure of bmDCs to SMAs 11a or 11i before stimulation with LPS in vitro significantly 310 
inhibits the number of DLN Ag-specific IL-17+CD4+ and IFN-Ȗ+CD4+ T cells generated 311 
compared to LPS-DCs following transfer of the DCs in vivo. This is likely a result of the 312 
reduced levels of IL-12, TNF-ĮDQG,/-6, key cytokines required for the differentiation of 313 
TH1/TH17 cells
35, produced by these DCs compared to LPS-DCs. Suppression of TH17 314 
responses by helminth-modulated DCs has, as far as we are aware, previously been reported 315 
solely by Dowling et al who demonstrated that two molecules from F. hepatica ES only 316 
partially activate DCs, with consequent attenuation of OVA peptide-specific TH17 responses 317 
in vivo36. Interestingly neither of these molecules induced DCs to drive TH2 responses in vivo, 318 
which is also shared with our data with SMA-modulated DCs. Indeed, none of the SMAs 319 
appeared to promote the production of IL-4 either in vitro or in vivo suggesting that while 320 
they can suppress TH1/TH17 responses, like ES-62, they may not actually drive the 321 
µRSSRVLQJ¶7H2 phenotype (if anything, the opposite). The use of in vitro helminth-modulated 322 
DCs to treat or ameliorate disease has been demonstrated in several murine models of 323 
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inflammatory disorders suggesting that DCs can play a central role in regulating the 324 
pathogenesis of autoimmune diseases such as arthritis, MS and colitis13±15. Here we 325 
demonstrate that transfer of bmDCs treated in vitro with 11a plus 12b protects against the 326 
development of inflammatory CIA in recipient mice. Of the four sulfones found to modulate 327 
DC responses, SMAs 11a and 12b were chosen for this model as their protective effect in 328 
CIA has already been established: although both SMAs act by mimicking ES-62 in 329 
downregulating MyD88 expression to subvert IL-1R/TLR responses, 11a appears primarily 330 
to mediate protection through suppression of downstream IL-17 responses while 12b acts 331 
predominantly to limit IL-ȕSURGXFWLRQE\WDUJHWLQJWKHLQIODPPDVRPHYLDFRXQWHU-332 
regulatory NRF2 signalling9,11. Thus, it was hypothesised that employing them in 333 
combination to target two pathogenic axes, could maximise any potential protective effects in 334 
this model. Protection was indeed observed and was associated with significantly lower 335 
levels of IL-17+CD4+ cells and IL-17+CD4- cells in the dLNs compared to PBS- and RPMI 336 
DC-treated mice, as well as reduced IL-17 and IL-ȕH[SUHVVLRQLQWKHMRLQW. IL-17 was also 337 
found to be decreased in the joints of mice treated with F. hepatica total extract, whilst DC 338 
matured with CpG (FTegDCs) and dLN cells from these mice showed reduced levels of IFN-339 
ȖDQG,/-17 when stimulated ex vivo with type II collagen (CII)13. This indicates that 340 
suppression of IL-17 responses may be a common mechanism by which helminths can 341 
ameliorate experimental models of arthritis. This could reflect that the induction of IL-10-342 
producing T regulatory (Treg) cells appears to be a key mechanism utilised by several 343 
helminths to prolong their survival within the host37 and certainly, there are reports that 344 
helminth-matured DCs can modulate inflammatory disease via an increase in IL-10 or 345 
generation of Treg cells. For example, adoptive transfer of DCs matured with Hymenolepis 346 
diminuta antigen confers protection against the development of experimental colitis and this 347 
is dependent on the production of IL-10 by cells of the adaptive immune system15. Also, the 348 
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protection afforded by FTegDCs was associated with an increase in FOXP3+CD25+CD4+ 349 
Treg cells, which were able to confer protection when transferred into recipient mice13.  In 350 
contrast to these models of immunomodulation by helminth infection/helminth Ag, we found 351 
no differences in the proportion of IL-10+FOXP3+CD4+, IL-10+CD4+ or IL-10+CD4- cells in 352 
the dLNs of any of the mice indicating that this is not a mechanism employed by SMA-353 
treated DCs to down-regulate CIA. This is consistent with previous findings with ES-62, 354 
which has consistently been found not to promote Treg responses but rather to act on effector 355 
cells to suppress inflammatory responses12,20,24. However, ES-62 has also previously been 356 
shown to induce protective IL-10-producing Breg cells25 and, although we did not examine 357 
effects on the various reported Breg populations directly in this present study, we did not 358 
observe an increase in IL-10 production and expression in draining lymph node CD4- cells: if 359 
IL-10+ regulatory B cells (B10 cells) had been affected, we might have expected to observe 360 
some increases in this population. Hence, we can only assume therefore that such cells are 361 
not generated via the DC-T cell interactions that would be promoted by adoptive transfer of 362 
SMA-pulsed DCs. ES-62 SMA-mediated protection was also not associated with a difference 363 
in antibody responses between SMA DC-treated mice and PBS or RPMI DC-treated mice 364 
despite ES-62 being previously shown to skew the humoral immune response from an IgG2a-365 
dominant to IgG1-dominant anti-CII response23. However, PC-BSA, which has been shown 366 
to mimic ES-62-mediated protection in CIA, did not have any effect on antibody responses38.  367 
Collectively, our data highlight the importance of DCs in regulating pathology in CIA and 368 
also provide insight into the mechanism of SMA-mediated protection as the modes of action 369 
(targeting IL-17 and IL-1E production) of the SMA-DCs closely mimic the mechanisms by 370 
which direct administration of these SMAs protects mice from CIA. In addition, these data 371 
demonstrate that, despite ES-62 and the SMAs having multiple potential targets within the 372 
immune system9,11,12, many of their effects can simply be recapitulated by transfer of DCs 373 
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exposed to these products.  Thus, in addition to adding to our knowledge of the mechanism of 374 
SMA-mediated protection, these data pinpoint DCs as a potential therapeutic target in RA. 375 
This is potentially highly useful information, as the drugs available against RA remain 376 
inadequate: for example, although cytokine blockers such as infliximab (targeting TNF-Į) 377 
have had some success, the number of patients achieving remission remains low8. Thus, new 378 
therapeutics are required, and the SMAs, due to their anti-inflammatory properties, allied to 379 
the ease and low cost of their production, are attractive drug candidates. Once again, it has 380 
must be emphasised therefore, that it is important to understand how they function and the 381 
cells they target, and ultimately the optimum structure of compound to employ. Compound 382 
optimisation will necessarily take into account pharmacokinetics, toxicity, and metabolism. 383 
As things stand, all four SMAs selected from the in vitro cytokine screen are sulfones 384 
(Structures in Figure 1), indicating that replacing phosphorus with sulphur (which results in 385 
intrinsically non-hydrolysable isosteres of phosphates) does not prevent the generation of 386 
compounds that mimic the anti-inflammatory effects of ES-¶VPC group. The four 387 
compounds each contain a two-carbon methylene chain between the sulfone group and 388 
choline derivative but vary slightly in their aromatic substituents and secondary 389 
amide/choline derivative and this may help explain the subtle differences in terms of their 390 
immunomodulatory effects. Specifically, 11a and 12b contain bromine and a methyl group 391 
respectively at C4 on their aromatic ring while 11e and 11i contain fluorine at C3 and C4 392 
respectively. In addition, 11a, 11e and 11i are all tertiary dimethyl amines while 12b is a 393 
quaternary ammonium salt, making it permanently positively charged, which would be 394 
expected to have a significant impact on E¶Vability to interact with receptors and gain 395 
access to the cell and intracellular compartments11. Clearly as alluded to earlier, further 396 
consideration/analysis is required in this area but ultimately it may be possible to explain 397 
such observations as why 12b targets ERK and p38 MAPKs whilst the other SMAs do not.   398 
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In conclusion, we have demonstrated the anti-inflammatory effects of SMAs of the helminth 399 
product ES-62 on DCs in vitro and in vivo and show that treatment with SMA-treated DCs is 400 
sufficient to prevent the development of CIA in mice. These data therefore highlight the 401 
therapeutic potential of DCs as a key target cell for SMA-mediated protection against disease.  402 
  403 
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Methods 404 
Animals 405 
Unless indicated otherwise, all mice were specified pathogen-free and maintained under 406 
standard ad libitum conditions at the Universities of Strathclyde and Glasgow SPF Biological 407 
Services Facilities. All experimental procedures were approved by, and performed in 408 
accordance with, the Animal Welfare and Ethical Review Body at the University of Glasgow, 409 
the Ethical Review Board of the University of Strathclyde and UK Home Office Regulations 410 
and Licenses PPL 60/4300 and PIL 60/4554. Male 6-8 week-old BALB/c or C57BL/6 mice 411 
were used to generate bone-marrow derived dendritic cells (bmDCs) and were bred at the 412 
University of Strathclyde for all experiments except the adoptive transfer experiment where 413 
the mice were purchased from Charles River Laboratories (Tranent, Scotland). For the in 414 
vitro co-culture experiments and in vivo adoptive transfer experiments, mice homozygous for 415 
the transgenic TCR which is specific for a chicken ovalbumin peptide (OVA323-339) in the 416 
context of I-Ad (D0.11.10 on a BALB/c background) were used as T cell donors22. Collagen 417 
(CII)-induced arthritis (CIA) was induced in male DBA/1 mice (10 weeks; Harlan Olac; 418 
Bicester, UK) and these mice were also used to generate bmDCs for use in the CIA study. 419 
DBA/1 animals were maintained in the Biological Services Unit of the University of 420 
Glasgow in accordance to the UK Home Office Licences PPL 60/4314, PIL IC9B4F104 and 421 
PIL I675F0C46 and the Ethics Review Board of the University of Glasgow. Arthritis was 422 
induced by intradermal immunization with CII HPXOVLILHGZLWKFRPSOHWH)UHXG¶VDGMXYDQW423 
0'%LRVFLHQFHVRQGD\LQMHFWLRQYROXPHȝO) and with CII in PBS intraperitoneally 424 
RQGD\LQMHFWLRQYROXPHȝODQGVFRUHGIRUGHYHORSPHQWRIDUWKULWLVDVSUHYLRXVO\425 
described23. Mice were inoculated with bmDCs that had either been treated with SMAs for 18 426 
hours or maintained in complete RPMI 1640 (containing 2 mM glutamine, 50 U/ml 427 
penicillin, 50 µg/ml streptomycin and 10% FCS; cRPMI) alone, on days -2, 0 and 21. 428 
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Animals were culled on day 35 and the blood, paws and popliteal draining lymph nodes 429 
(dLNs) harvested for analysis.  430 
In vitro cell culture 431 
BmDCs were prepared essentially as described previously39. Briefly, bone marrow was 432 
obtained from the femurs and tibias of BALB/c mice and cells grown in cRPMI 1640 433 
supplemented with 10 ng/ml GM-CSF (PeproTech, London, UK) at 37°C in 5% CO2 for 8 434 
days with fresh medium supplemented with GM-CSF added on days 3 and 6. On day 8 435 
loosely adherent cells were harvested and found to be 75-85% CD11c+MHC II+, as 436 
determined by flow cytometry.  Such cells were employed as bmDCs and were treated with 437 
SMAVȝJPOIRUKRXUVEHIRUHVWLPXODWLRQZLWK3$03s/36QJPORUȝJPO438 
Escherichia coli 055:B5, Sigma-Aldrich); BLP (100 ng/ml; Pam3CSK4, InvivoGen, Toulouse, 439 
FranceDQG&S*ȝ06RXUFHV%LRVFLHQFHV1RWWLQJKDP8.IRUKRXUVDQGWKH440 
supernatants recovered for cytokine analysis. Additionally, BmDCs were pre-treated with 441 
SMAs (5 ȝJPO) for 18 hours, primed with LPS (100ng/ml) for 5 hours and stimulated with 442 
ATP (Sigma-Aldrich) for 30 minutes and the supernatants recovered for IL-1E analysis.  For 443 
bmDC-T cell co-cultures, bmDCs were incubated with SMAs for 18 hours, matured with 444 
LPS for 24 hours and then pulsed with OVA323-339 peptide (0-300 nM) before incubation with 445 
naïve T cells derived from OVA-specific DO.11.10 BALB/c mice for 3 days. Naïve T cells 446 
were isolated using Miltenyi magnetic bead technology, as CD62L+CD4+ T cells. 447 
ELISA 448 
Interleukin-6 (IL)-6, IL-12p40, TNF-ĮDOO%'3KDUPLQJen, Oxford, UK), IL-12p70, IFN-Ȗ449 
IL-4 (all eBioscience, Hatfield, UK) and IL-17 and IL-1E (R&D Systems, Abingdon, UK) 450 
secretion was measured using enzyme-linked immunosorbent assays (ELISAs) according to 451 
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WKHPDQXIDFWXUHU¶VLQVWUXFWLRQV7KHF\WRNLQHVZHUHGHWHFWHGXVLQJELRWLQ\ODWHGPRQRFORQDO452 
antibodies, streptavidin horseradish peroxidase (SAv-HRP) and TMB substrate. 453 
 454 
Flow cytometry 455 
Expression of costimulatory molecules on DCs was quantified by flow cytometry using anti-456 
CD11c-Pe/Cy7, anti-CD86-PerCP (both BioLegend), and biotinylated anti-CD40 457 
(eBioscience; detected by streptavidin-APC/Cy7, BD Pharmingen) antibodies, with the 458 
gating strategy shown in Supplementary Figure 1. Popliteal DLN cells (106/ml) from in vivo 459 
models were incubated ± 50 ng/ml PMA plus 500 ng/ml ionomycin for 1 h before addition of 460 
10 µg/ml Brefeldin A (Sigma-Aldrich, UK) for a further 5 h at 37oC with 5 % CO2. 461 
Phenotypic markers were labelled using anti-CD4-FITC or anti-CD4-PerCP (both BD 462 
Bioscience) and anti-KJ1.26-APC (eBioscience) before the cells were fixed and 463 
permeabilized employing the FOXP3 Fix/Perm buffer set according to eBioscience 464 
protocols40. Cells were then labelled using anti-IL-17A-PerCP or APC/Cy7, anti-IFN-Ȗ-APC 465 
or PeCy7, anti-IL-4-PE, anti-IL-10-PE and anti-FOXP3-APC (all eBioscience) antibodies for 466 
30 min prior to flow cytometry. Data were acquired using a FACSCanto immunocytometry 467 
system (BD Pharmingen) with samples gated according to appropriate isotype and 468 
fluorescence minus one controls and analysed using FlowJo software (Tree Star Inc, OR, 469 
USA, version 7.6.1). The gating strategy for the adoptive transfer model is shown in 470 
Supplementary Figure 2 whilst those for analysis of DLN cells from CIA mice are shown in 471 
Supplementary Figures 3 and 4. 472 
 473 
qRT-PCR 474 
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%P'&VZHUHWUHDWHGZLWK60$VȝJPOIRUKRXUVand then matured with LPS (100 475 
ng/ml) for 4 hours before extraction of RNA using the RNeasy Plus Mini kit from Qiagen 476 
+LOGHQ*HUPDQ\DFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV RNA was transcribed using 477 
the High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Life Technology) 478 
and duplicate PCR amplifications were performed using the StepOne PlusUHDO-time PCR 479 
system DFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV(Applied Biosystems). Applied 480 
Biosystems assay kits for IL-6 (Mm00446190_m1), TNF-D (Mm00443259_g1), IL-12p35 481 
(IL-12a, Mm00434165_m1), IL-12p40 (IL-12b, Mm00434174_m1), IL-1E 482 
(Mm00434228_m1), NLRP3 (Mm04210224_m1) and HMOX-1 (Mm00516005_m1) were 483 
used. Data were analysed by RQ Manager software (Applied Biosystems) and normalized to 484 
the reference reporter glyceraldehyde 3-phosphate dehydrogenase (GAPDH, 485 
Mm99999915_g1). 486 
 487 
Signalling Assays 488 
%P'&VZHUHWUHDWHGZLWK60$VȝJPOIRUKRXUV, then matured with LPS (100 ng/ml) 489 
for 30 minutes. Nuclear cell extracts were obtained using the Nuclear Extract kit and the 490 
levels of NF-ț%SLQWKHQXFOHXVGHWHUPLQHGXVLQJa TransAM NF-ț%S7UDQVFULSWLRQ491 
)DFWRU$VVD\NLWDFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV (Actif Motif, LaHulpe, 492 
Belgium).  Likewise, for Fast Activated Cell-Based ELISA (FACE) assays, bmDCs were 493 
WUHDWHGZLWK60$VȝJPOIRUKRXUV, then stimulated with LPS (100 ng/ml) for 10 494 
minutes on 96-well plates that were pre-coated with Poly-l-Lysine (Sigma-Aldrich). Cells 495 
were fixed in 4% (w/v) paraformaldehyde (Santa Cruz Biotechnology, Texas, USA) and the 496 
expression of total and phosphorylated forms of ERK and p38 MAPKs determined as 497 
described previously7. 498 
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  499 
Analysis of joint pathology and cytokine expression in the joints 500 
Representative paws from each group in the CIA model were used to examine joint pathology 501 
and cytokine expression. Decalcified joint tissue section preparation, Trichrome staining and 502 
cytokine detection by immunofluorescence were undertaken as previously described11,12,40. 503 
To detect cytokine expression, the joint sections were de-waxed in Xylene, and re-hydrated 504 
by incubation with decreasing concentrations of ethanol before incubation in citrate buffer 505 
(10mM citric acid, 0.1% Tween, pH 6.0) for antigen retrieval. Sections were then blocked 506 
against endogenous biotin (Molecular Probes, Oregon, USA) and incubated with goat anti-507 
mouse IL-17 antibody (Abcam, Cambridge, UK) or rabbit anti-mouse IL-1E antibody 508 
(Abcam) for 12 h at 4 qC. Signal was detected using biotinylated secondary antibodies (anti-509 
goat IgG for IL-17 and anti-rabbit IgG for IL-1E) and Streptavidin-Alexa Fluor647. Sections 510 
were then dehydrated by incubation in increasing concentrations of ethanol, mounted and 511 
counterstained using VECTORSHIELD mounting medium containing DAPI (Vector 512 
Laboroatories, California, USA). Immunofluorescence images were obtained using an LSM 513 
510 META confocal laser coupled to an Axiovert 200 microscope (Zeiss) and analysed using 514 
Zeiss LSM Image Browser software (Oberkocken, Germany). 515 
 516 
Statistical Analysis  517 
Parametric data were analysed by Student t test, one-way ANOVA with Bonferroni post-test 518 
or Fishers LSD test. Non-parametric data were analysed using Mann-Whitney U or Kruskal-519 
Wallis with Dunns post-test. In all cases * p < 0.05, ** p < 0.01 and *** p < 0.001. 520 
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Figure Legends 639 
Figure 1: Small molecule analogues (SMAs) of the parasitic worm product ES-62 inhibit PAMP-640 
induced cytokine production. The structures of SMAs 11a (A), 11e (B), 11i (C) and 12b (D) are 641 
shown. BmDCs were incubated with SMA (5 ȝg/ml) for 18 hours before stimulation with LPS, BLP 642 
(both 100 ng/ml) or CpG (0.1 ȝM) and the production of IL-6 (E) TNF-Į (F) and IL-12p70 (G) was 643 
measured by ELISA. Data are expressed as means (of triplicate determinations) ± SD and analysed 644 
using one-way ANOVA with Bonferroni post-test where * p < 0.05; ** p < 0.01; *** p < 0.001 645 
compared to relevant PAMP. All data are representative of at least two independent experiments.  646 
  647 
Figure 2: ES-62 SMAs target cytokine production at the level of transcription and display 648 
differing effects on the activation of MAPKs and NF-țBp65. BmDCs were treated with SMAs 649 
11a, 11e, 11i or 12b (5 ȝg/ml) for 18 hours, matured with LPS for 4h, before extracting RNA and 650 
analysing the expression levels of IL-12p40 (A), IL-12p35 (B), IL-6 (C) and TNF-Į (D) by qRT-PCR. 651 
Cytokine expression was normalised to GAPDH and the levels of mRNA in SMA+LPS (from all 652 
experiments [n=3]) compared to LPS (100%) DC calculated and compared using a one sample t test. 653 
Results are expressed as the mean ± SEM. BmDCs were treated with SMA 12b for 18 hours and then 654 
stimulated with LPS for 10 minutes and the levels of total and phosphorylated p38 (E) and ERK (F) 655 
measured by fast-activated cell ELISA (FACE). Phosphorylated p38 or ERK1/2 absorbance were 656 
normalised to the corresponding total p38 or ERK1/2 absorbance and the data expressed as means (of 657 
triplicate determinations) ± SD. Data were analysed using one way ANOVA with Bonferroni post-test 658 
where for statistical analysis, * p < 0.05; ** p < 0.01. As above, bmDCs were incubated with SMAs 659 
for 18 hours before stimulation with LPS for 30 minutes and the level of p65 activation in duplicate 660 
samples measured by TransAM (G).  All data are representative of at least two independent 661 
experiments. 662 
  663 
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Figure 3: ES-62 SMAs modulate bmDC priming of T cell responses. BmDCs were incubated with 664 
SMAs for 18 hours, stimulated with LPS (100 ng/ml) for 24 hours, and CD40 (A) and CD86 (B) 665 
expression by CD11c+ cells measured by flow cytometry in term of % cells (upper panels) and 666 
Median Fluorescence Intensity (MFI; lower panels). (C) BmDCs from BALB/c mice pre-incubated 667 
with/ZLWKRXW60$VȝJP/VWLPXODWHGIRUKRXUVZLWK/36DQGWKHQSXOVHGZLWK29$SHSWLGH668 
were co-cultured with naive OVA-specific CD4+ T cells for 3 days before measuring IFN-Ȗ release by 669 
ELISA. Inhibitory effects were observed at several peptide concentrations over two independent 670 
experiments and the results shown are for 300 ȝM. Data are presented as means ± SD and were 671 
analysed by one way ANOVA with Bonferroni post-test where * p < 0.05; ** p < 0.01; *** p < 0.001. 672 
)RUSDQHO&³1'´ QRWGHWHFWHG%P'&VZHUHLQFXEDWHGZLWKwithout SMA 11a or 11i and pulsed 673 
with OVA overnight before stimulation ± LPS for 24 hours and injected into BALB/c mice that had 674 
received 106 naïve CD4+KJ1.26+ T cells from donor DO11.10 mice 24 h previously. The number (D) 675 
and percentage (E) of KJ1.26+ CD4 T cells in the popliteal dLNs of adoptively transferred mice on 676 
different days is shown. Data are expressed as the mean percentage of 3 mice per group per day and 677 
the error bars (SEM) are omitted for clarity. On days 3 and 5 all treatments except OVA+SMA on day 678 
3 and OVA+11i on day 5 demonstrated a significant increase in the proportion of KJ1.26+CD4+ T 679 
cells compared to RPMI DCs alone. The numbers of these T cells on day 5 (F) and their expression of 680 
intracellular IL-17 (G, H), IFNȖ (I, J) and IL-4 (K, L) on this day were analysed by flow cytometry. 681 
Data are expressed as mean ± SEM for 3 mice per group and analysed using Fishers LSD test where * 682 
p < 0.05, ** p < 0.01 and *** p < 0.001; **** p < 0.0001 compared to RPMI; * p < 0.05 compared to 683 
OVA DCs and * p < 0.05 and ** p < 0.01 compared to OVA + LPS DCs.  684 
 685 
Figure 4:  SMA-treated dendritic cells protect against CIA. DBA/1 bmDCs were incubated with 686 
SMAs 11a and 12b (2.5 ȝg/ml of each) and CII overnight, washed, and injected into CIA-mice on day 687 
-2, 0 and 21. Disease is shown by mean arthritic score (A) (PBS, n = 3; RPMI-DCs and SMA-DCs, n 688 
= 6). Data are expressed as means ± SEM and analysed using an unpaired t test where * p < 0.05 689 
compared to PBS. Joint sections (x10 magnification) from individual mice representative of each 690 
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treatment group were assessed for histopathology by Trichrome staining (B). CII-specific IgG1 (C) 691 
and IgG2a (D) levels in serum samples from naïve (no CII treatment; n=3), PBS- (n=3), RPMI DC- 692 
(n=6) and SMA DC- (n=6) treated mice were determined by ELISA. Results are expressed as mean 693 
(of duplicate determinations) for each mouse in the group. The percentage of IL-10+ FOXP3+ CD4+ T 694 
cells (E), IL-10+ CD4+ T cells (F) and CD4-IL-10+ cells (G) in the DLNs from all paws from CIA-695 
mice treated with PBS, RPMI-DCs or SMA-DCs were analysed by flow cytometry. Results from 696 
individual mice in each group are shown; numbers as above. Data were analysed using one-way 697 
ANOVA employing Fishers LSD test. 698 
 699 
Figure 5: SMA-treated bmDCs inhibit IL-17 and IL-1ȕ responses. The percentage of IL-17-700 
expressing CD4+ cells (A) and IL-17-expressing CD4- cells (B) in the DLNs from paws from naïve or 701 
CIA-mice treated with PBS, RPMI-DCs or SMA-DCs was determined by flow cytometry. Results 702 
from individual mice in each group (naïve n=3, PBS n=3, RPMI-DC n=6 and SMA-DC n=6) are 703 
shown. Data are compared using one way ANOVA and Fishers LSD test where * p < 0.05 ** p < 704 
0.01. (C) Joint sections from individual mice representative of each treatment group were assessed for 705 
IL-17 and IL-1ȕ expression by immunofluorescence (magnification 20x; scale bars 20 ȝm). The 706 
strong IL-1ȕ positive staining in the SMA-DC image (denoted by white arrow) reflects high 707 
production of IL-1ȕ by keratinocytes in the skin and is an additional control for antibody specificity40. 708 
BmDCs were incubated with the indicated SMAs (5 ȝg/ml) for 4 hours, the RNA was extracted and 709 
the expression levels of IL-1ȕ (D), NLRP3 (E) and HMOX-1 (F) measured by qRT-PCR. Cytokine 710 
expression was normalised to GAPDH and then expressed as a fold change with respect to the 711 
relevant RPMI control. The data shown are collated from 3 independent experiments and presented as 712 
means of mean values (triplicate assays in each experiment) ± SEM, n=3.  (G) BmDCs were 713 
incubated with the indicated SMAs (5 ȝg/ml) for 18 hours before stimulation with BLP for 24 hours 714 
and the levels of IL-1ȕ measured by ELISA. Data are expressed as means (of triplicate 715 
determinations) ± SD. (G) BmDCs were incubated with the indicated SMAs (5 ȝg/ml) for 18 hours 716 
before being primed with LPS (100 ng/ml) for 5 hours then stimulated with 1 mM ATP for 30 717 
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minutes and the levels of IL-1ȕ measured by ELISA. Data are expressed as means (of triplicate 718 
determinations) ± SD.  Data in D-G were analysed using students t-test (or Wilcoxin signed rank test 719 
for normalised qRT-PCR data) where * p < 0.05, ** p < 0.01, *** p<0.001, **** p < 0.0001; data in 720 
G & H are from single experiments that are representative of at least two independent experiments.  721 
 722 
